Taro.Ns
TARO.NS operates in the healthcare services and equipment industry, primarily generating revenue through the distribution of medical equipment and supplies.
Business. TARO.NS operates in the healthcare services and equipment industry, primarily generating revenue through the distribution of medical equipment and supplies.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TARO.NS operates in the healthcare services and equipment industry, primarily generating revenue through the distribution of medical equipment and supplies.
TARO.NS maintains a debt-to-equity ratio of 0.54, indicating a moderate level of leverage, and a current ratio of 1.38, suggesting adequate short-term liquidity to cover its obligations. However, the company's free cash flow is negative at -700,720,000 INR, which may signal pressure on liquidity and the need for external financing or operational improvements.
The company's profitability is reflected in a return on equity (ROE) of 4.72% and a return on assets (ROA) of 2.76%. These figures are below the industry median for ROE and ROA, indicating that TARO.NS is underperforming its peers in terms of capital efficiency and asset utilization.
TARO.NS does not disclose specific segment or geographic revenue breakdowns in the available data, making it difficult to assess the concentration of its revenue sources or geographic exposure. Analysts and investors should monitor any future disclosures for insights into the company's diversification strategy.
The company's revenue for the latest period is 3,924,140,000 INR, and while no specific growth trajectory is provided, the negative free cash flow and capital expenditure of -1,517,070,000 INR suggest that the company is investing heavily in its operations, which could be a precursor to future growth.
TARO.NS faces a medium liquidity risk, as indicated by its negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure expected. However, the negative free cash flow and high capital expenditure may necessitate future financing, which could lead to dilution.
Recent events, including analyst estimates and financial performance, indicate a mixed outlook. The mean recommendation from analysts is 2.00, which is a "Hold" rating, with one "Buy" recommendation and no "Strong Buy" or "Sell" ratings. The last actual EPS was 5.60 INR, and the last actual revenue was 3,924,140,000 INR.
- TARO.NS has a moderate level of leverage and adequate short-term liquidity.
- The company's profitability metrics are below the industry median, indicating underperformance in capital efficiency and asset utilization.
- The company is investing heavily in its operations, as evidenced by a significant capital expenditure.
- TARO.NS faces a medium liquidity risk due to its negative net cash position.
- Analysts have issued a "Hold" rating for the company, with one "Buy" recommendation and no "Strong Buy" or "Sell" ratings.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- TARO.NS Market data — financials · 2026-05-29
- Tarsons Products Ltd Market data — analyst estimates · 2026-05-29